Digbi Health Expands Its Employer GLP-1 Telehealth Service to Include Self-Pay Access for Employees and Family Members

MOUNTAIN VIEW, Calif., November 18, 2025 /Digbi Newswire/ -- Digbi Health today announced the expansion of its nationally deployed employer-sponsored GLP-1 telemedicine program to include a self-pay access and fulfillment pathway for employees and eligible family members who may not have access to GLP-1 weight-loss medications through their employer-sponsored programs.

The expansion makes the first precision biology-powered telehealth service accessible to a broader population within employer ecosystems, streamlining every step of the GLP-1 journey from clinical evaluation to prescription to fulfillment.

What the program includes

• Clinically supervised access to FDA-approved GLP-1 medications including Wegovy®, Ozempic® and Zepbound®, with an introductory cash price of $199 per month for Ozempic® and Wegovy® injection pens for Digbi self-pay users, with transparent pricing and no hidden fees.
• Flexible fulfillment, including in-pharmacy pickup for Wegovy® or Zepbound® pens and home delivery for Zepbound® vial formulations.
• Virtual consultations with licensed clinicians who determine eligibility, order all required labs at no cost, and write prescriptions when medically appropriate.
• Continuous clinical oversight to track progress, manage side effects and adjust titration or care plans.
• Precision biology diagnostics including DNA testing, gut microbiome testing and continuous glucose monitoring to identify insulin resistance, glucose dysregulation and biological factors that influence GLP-1 effectiveness.
• AI-powered nutritional guidance to optimize protein intake, reduce GI symptoms, improve gut health and support natural GLP-1 production.

The biology problem: why many GLP-1 users quit or don't respond

While GLP-1 medications have reshaped metabolic health, real-world outcomes remain inconsistent:

• 30–40% of users experience significant GI-related adverse effects.
• Many experience hair loss, muscle loss, constipation and nutrient deficiencies.
• Nearly 25% lose less than 5% of their body weight, driven by insulin resistance, impaired glucose control or microbiome-mediated variability in drug response.

These issues drive early discontinuation, creating avoidable waste and limiting long-term outcomes. Digbi Health's precision biology approach addresses the underlying metabolic drivers of GLP-1 tolerability and effectiveness.

The integrated care model

Every Digbi-covered and Digbi self-pay member receives clinical prescribing and titration pathways; DNA analysis for metabolic risk, appetite regulation, weight regain risk and drug responsiveness; gut microbiome testing to identify inflammation, digestive vulnerabilities and GLP-1 degradation pathways; continuous glucose monitoring to personalize glucose control and predict medication responsiveness; AI-driven meal scoring and nutrition coaching informed by glucose, microbiome and genetic insights; and GI care and food-as-medicine interventions to enhance natural GLP-1 production.

GLP-1 tolerability and effectiveness depend heavily on biology. By expanding self-pay access to employees and their families, we ensure that more people receive safe, personalized care — guided by genetics, the microbiome, and glucose data — to improve outcomes and reduce avoidable discontinuation.

— Ranjan Sinha, Founder and CEO, Digbi Health